Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BGross who wrote (35)	3/13/1997 6:57:00 PM
From: Steve	of 370

Dear B: Anyone knows that investing in R&D stage biotech companies offers just about the highest risk/reward profile next to going to Vegas. As such, there are no certainties that anything commercial/profitable will come out of the lab. However, I believe that Vion is playing in a great part of the research, namely antiviral and oncology products. Their licensing agreements with Yale may prove to offer them solid FUTURE therapeutic products. All of Vion's five principal areas of research: Hypoxic Cancer, Cell Therapeutics, Alkylating Agent Prodrugs, Ribonucleotide Reductase Inhibitors, Nucleioside Analogs and Gene Therapy may become big hits, but that's the big IF. As far as having a great board of directors, I agree. However, that means very little if no commercial products are ultimately developed. Long way of saying . . . . It's a gamble, but with Vion's relatively tiny market cap, low visibility with the analyst and promise of therapeutic products, I've been willing to be in this one for the long run. Good luck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next